Last reviewed · How we verify
Dexilant (DEXLANSOPRAZOLE)
Dexlansoprazole inhibits gastric acid secretion by blocking the (H+, K+)-ATPase enzyme, known as the proton pump, in gastric parietal cells.
At a glance
| Generic name | DEXLANSOPRAZOLE |
|---|---|
| Sponsor | Takeda |
| Drug class | Proton Pump Inhibitor [EPC] |
| Target | (H+, K+)-ATPase |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
| First approval | 2009 |
| Annual revenue | 300 |
Mechanism of action
Dexlansoprazole is part of a class of drugs called proton-pump inhibitors. It works by specifically targeting and inhibiting the (H+, K+)-ATPase enzyme, which is responsible for the final step in acid production in the stomach. By blocking this enzyme, dexlansoprazole reduces the amount of acid produced, helping to treat conditions related to excess stomach acid.
Approved indications
- Erosive esophagitis
- Gastroesophageal reflux disease
- Maintenance of Healing Erosive Esophagitis
- Peptic ulcer
Common side effects
- Diarrhea
- Abdominal Pain
- Nausea
- Upper Respiratory Tract Infection
- Vomiting
- Flatulence
Drug interactions
- atazanavir
- clopidogrel
- dasatinib
- dasatinib
- delavirdine
- erlotinib
- erlotinib
- itraconazole
- ketoconazole
- nelfinavir
- nelfinavir
- ponatinib
Key clinical trials
- A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old (PHASE2)
- Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding" (PHASE3)
- Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention (NA)
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia (NA)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
| 8173158 | 2030-03-17 | Method of Use |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexilant CI brief — competitive landscape report
- Dexilant updates RSS · CI watch RSS
- Takeda portfolio CI